Overview

* Coherus Q2 2025 LOQTORZI net revenue rises 36% to $10 mln

* Sales beat analyst expectations, driven by higher demand and inventory restocking

* Coherus completed UDENYCA divestiture, boosting cash and reducing obligations

Outlook

* Coherus on track for data readouts for CHS-114 and casdozokitug in 1H 2026

* Company plans to combine LOQTORZI with pipeline candidates for new indications

* Coherus aims for external partnerships to expand product labels

* Company has a cash runway through 2026

Result Drivers

* LOQTORZI DEMAND - Higher patient demand and inventory restocking drove 36% revenue growth for LOQTORZI in Q2 2025

* NCCN GUIDELINES - Revision in NCCN guidelines granting LOQTORZI preferred status for NPC indication contributed to strong demand growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $10.25 $10.10

mln mln (5

Analysts

)

Q2 Beat $1160777 -$0.32

Adjusted 10 (2

EPS Analysts

)

Q2 Miss -$39.03 -$38.70

Adjusted mln mln (1

Net Analyst)

Income

Q2 Net $297.77

Income mln

Q2 -$45.49

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Coherus Oncology Inc ( CHRS ) is $6.50, about 85.9% above its August 6 closing price of $0.92

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)